DDInter905 DDInter1625
Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth
Rubella virus vaccine is a live attenuated virus vaccine for active immunization against rubella (German measles) that is subcutaneously administered. It is prepared from RA 27/3 strain of live attenuated rubella virus. Rubella is a common childhood disease, caused by rubella virus (togavirus).
Idelalisib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Idelalisib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cannabidiol
Idelalisib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eltrombopag
Idelalisib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Satralizumab
Idelalisib {u} may lead to a major life threatening interaction when taken with {v} Baricitinib
Idelalisib {u} may lead to a major life threatening interaction when taken with {v} Vinorelbine
Idelalisib may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Idelalisib may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag
Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab
Idelalisib may lead to a major life threatening interaction when taken with Baricitinib
Idelalisib may lead to a major life threatening interaction when taken with Vinorelbine